Sartorius Stedim Biotech SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Sartorius Stedim Biotech SA Confirms FY 2013 Revenue Guidance
Sartorius Stedim Biotech SA announced that, based on its results from the first half of fiscal year 2013, it confirms its full-year targets for fiscal year 2013 and expects its revenue to grow by approximately 8% to 11% in constant currencies. The Company reported a revenue of EUR 544 million for fiscal year 2012. According to I/B/E/S Estimates, analysts on average are expecting the Company to report revenue of EUR 597 million for fiscal year 2013.
Latest Developments for Sartorius Stedim Biotech SA
Latest Key Developments in Medical
- St. Jude Medical Inc announces CE Mark approval and first use of FlexAbility Ablation Catheter
- Teleflex Inc receives FDA clearance for ARROW-Clark VectorFlow Chronic Hemodialysis Catheter
- Sartorius Stedim Biotech SA sees FY 2014 revenue guidance to reach upper end of prior range
- Sartorius AG confirms FY 2014 revenue guidance
- Share this
- Digg this